Trials Sponsors Conditions Drugs Pricing

Conditions

Alzheimer's Disease

Keywords

Amyloid

Outcome Measures

Primary Outcomes (1)

Number of subjects with adverse events as a measure of safety and tolerability
0-96 hours post-dose

Study Arms (5)

NGP 555 25 mg

ACTIVE COMPARATOR

NGP 555 25 mg capsule and placebo by mouth once per day

Drug: NGP 555

NGP 555 50 mg

ACTIVE COMPARATOR

NGP 555 50 mg capsule and placebo by mouth once per day

Drug: NGP 555

NGP 555 100 mg

ACTIVE COMPARATOR

NGP 555 100 mg capsule and placebo by mouth once per day

Drug: NGP 555

Interventions

NGP 555Drug

Gamma-secretase modulator for the treatment of Alzheimer's disease

Also known as: NGP555

NGP 555 100 mgNGP 555 200 mgNGP 555 25 mgNGP 555 300 mgNGP 555 50 mg

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 55 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

Male and female volunteers aged 18-55 yrs and in good health as determined by medical history, physical examination, clinical laboratory studies, electrocardiograms (ECGs), vital signs, and investigator judgment
Volunteer voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent prior to performing any of the screening procedures

Sponsors & Collaborators

NeuroGenetic Pharmaceuticals Inc
Industrylead

Study Sites (1)

WCCT

Cypress, California, 90630, United States

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders

Study Officials

Apinya Vutikullird, DO
WCCT
PRINCIPAL INVESTIGATOR

Enrollment

40 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: RANDOMIZED
Masking: QUADRUPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: PREVENTION
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 27, 2015

First Posted

August 27, 2015

Study Start

March 2015

Date type not reported

This date has not been verified as actual or estimated.

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (5)

NGP 555 25 mg

NGP 555 50 mg

NGP 555 100 mg

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

NGP 555 200 mg

NGP 555 300 mg

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (5)

NGP 555 25 mg

NGP 555 50 mg

NGP 555 100 mg

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

NGP 555 200 mg

NGP 555 300 mg

You may not qualify if:

Source record

Locations